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Abstract 
Sixteen cobalt(III) complexes incorporating one of the investigated 4N donor tripodal amines 
in the presence or absence of differently substituted hydroxamates have been synthesized and 
the effect of the nature of the N-donor, size of the chelates formed and the effect of the type of 
the substituent(s) at the hydroxamate moiety on the redox properties of the complexes have 
been studied. The crystal and molecular structures of the new complexes, [Co(uns-
penp)(H2O)Cl]Cl2.H2O (4), [Co(tren)(phebha)](ClO4)2 (11), 
[Co(tpa)(bha)](ClO4)2·C2H5OH·H2O (15) and [Co(tpa)(phebha)](ClO4)2 (16) have also been 
determined by single crystal X-ray diffraction method. Cyclic voltammetric (CV) results 
indicated the irreversible reduction of Co(III) in all the investigated complexes. Out of the 
four studied tripodal amines, abap was found to decrease the Co(III/II) reduction potential far 
below the region of bioreductants. Decreasing of two of the chains by one CH2 in tren 
compared to abap resulted in less negative reduction potential of the corresponding complex. 
Further positive shift was observed by introducing two (uns-penp), and especially three (tpa) 
pi-back-bonding pyridyl rings into the chains of tetramines. In agreement with literature 
results, the 3+ oxidation state of the central cobalt ion was found to be extremely stabilized in 
the ternary complexes containing the doubly deprotonated benzohydroximate, but the metal 
ion is significantly more reducible in the ternary complexes with mono-deprotonated 
benzohydroxamate/derivative ligands. Measurable effect was not found on the redox potential 
via introduction of chloro or nitro substituents in para position into the phenyl moiety of bha– 
(Cl-bha– and NO2-bha–). Significant positive shift (ca. 200 mV) was obtained, however, when 
RN = H was replaced by a phenyl ring in phebha– therefore complexes with this latter ligand 
can be likely candidates for the in vitro releasing of hydroxamates with proven biological 
activity. 
 
 
Introduction 
Hydroxamic acids (HA) with the general formula of RCC(O)NRN(OH) (where RC = 
alkyl or aryl; RN = H in primary derivatives, alkyl or aryl in secondary ones) are important 
class of biomolecules with their  significance  in a wide array of different  applications, e.g. in 
nature and medicine [1-3]. In addition to their well-known roles in the microbial iron-uptake 
[4] HAs are capable of inhibiting a variety of enzymes, including e. g. matrix  
metalloproteinases [3, 5, 6]. Extensive studies on hydroxamate-based compounds have 
resulted in the development of several drug candidates during the past ca. two decades, such 
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as batimastat and its orally bioavailable analogue, marimastat [7]. Moreover, suberoilanilide 
hydroxamic acid, SAHA, is an FDA-approved anticancer agent to treat cutaneous T-cell 
lymphoma [8]. A hydroxamic function, in its deprotonated form, typically bounds to metal 
ions via the five-membered „so-called” hydroxamate-type (O,O) chelate, but, with certain 
metal ions and doubly deprotonated primary derivatives, the hydroximate-chelate can also be 
formed [2,9]. There is no doubt that all the above-mentioned biological activities of HAs are 
in close correlation with their excellent metal ion binding capability. At least in some part, the 
selectivity and efficiency problems of hydroxamate-based drug candidates can also be 
associated with the interaction of their active forms with various endogeneous metal ions 
during their transportation to the target. To overcome the problem, chaperoning of the small 
drug molecule to the site of action in an inactive form and activation of it at the site have been 
investigated in a number of laboratories, e.g. by Hambley and his co-workers [10-14]. In their 
works, inactivation of the hydroxamate-based MMP (Matrix Metalloproteinases) inhibitors 
has been achieved via chelation of the hydroxamate binding group to the metal centre of 
kinetically inert Co(III) complexes.  Out of the several known approaches [14-17], the 
concept of the bioreduction in the environment of hypoxic tumours was envisaged in a 
number of works to solve selective activation of the chaperon pro-drug at the site of action 
[10-13, 15-16]. Cobalt complexes are of special interest as hypoxia selective prodrugs since 
many years, because of the very significant difference in lability between the complexes of 
cobalt(III) and cobalt(II) [18]. While the former complexes are inert, the latters show labile 
character. Consequently, reduction of the metal centre to the labile +2 oxidation state at 
hypoxic environment of tumour tissues allows releasing of the inhibitor molecule in its active 
form.      
Realization of the above concept requires compliance of the redox potential of the cobalt(III) 
complex with that of hypoxic tumors. To the best of our knowledge, accurately determined 
redox properties have not reported for hypoxic tumours yet, but a reduction potential range of 
-200 mV   ̶ -400 mV (vs. normal hydrogen electrode, NHE) is given in a paper to match that 
of cellular reductases [15], while near or lower than ca. -300 mV is suggested as appropriate 
potential for an ideal hypoxia-acivated pro-drug in another publication [10].           
As it is known from the literature, O-donor hydroxamate ligands alone are not able to 
decrease the redox potential of the [Co(H2O)6]3+/[Co(H2O)6]2+ system (ca. +1.8 V) down to 
the values above [19], but numerous ternary complexes, prepared by Hambley and his 
coworkers, consisting of a tripodal tetraamine tetradentate ligand and a hydroxamate have 
been found to fullfill this requirement [10-12]. Out of the high number of known tripodal 
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tetraamins [20], tris(2-methylpyridyl)amine (tpa) and tris(2-aminoethyl)amine (tren) were 
used to sysnthesize chaperons in the works cited in refs. 10-12, while the studied hydroxamic 
acids were the acetohydroxamic acid, benzohydroxamic acid, propionhydroxamic acid, 2-
(naphthalen-1-yl)hydroxamic acid [11,12], as well as the MMP inhibitor marimastate [10]. 
All of the investigated complexes showed irreversible reduction at the cobalt centre and the 
reduction potentials for the tren-containing complexes were always considerably lower than 
for the tpa-containing ones. This trend was suggested to be caused by the pi-acceptor 
behaviour of the tpa-pyridyl rings [12,16]. Significantly more negative reduction potential 
was found to belong to the hydroximate-containing complexes compared to the hydroxamate 
ones [12, 21]. The very low reduction potentials for the former complexes are thought to be 
beyond the redox value inside the cell and reduction of them with biological reductants is 
hardly possible [21].    
As a continuation of our previous investigations on Co(III) complexes of hydroxamic acids 
[19], synthesis and characterization of numerous ternary complexes of Co(III) formed with 
tripodal tetraamines involving different types of N-donors and chain lengths, as well as with 
hydroxamic acids have been performed in the present study. The formulae of the ligands are 
presented in Scheme 1.  
 
Scheme 1 
 
Because the reduction potential of the complexes is a vital parameter for the activation of the 
inactivated inhibitor via bioreduction, study of the structural effect of different tetraamines 
and also various substituents at the hydroxamic function on this parameter has been one of the 
major goals of this work.    
 
2. Experimental  
 
2.1 Materials and reagents 
CoCl2·6H2O, NaNO2, tris(2-aminoethyl)amine (tren), N-acetylethylenediamine, pyridine-2-
carboxaldehyde, phthalic acid anhydride, 3,3’-iminobis(propylamine), NaBH(OAc)3, 4-nitro-
benzoylchloride, 4-Cl-benzoylchloride, picolyl-amine, picolyl-chloride, nitrobenzene, 4-nitro-
toluene, 4-Cl-toluene, zinc powder, benzohydroxamic acid and various solvents were 
commercial products from Merck, SigmaAldrich, VWR and Reanal; and used as received. 
Tris(2-pyridylmethyl)amine (tpa) [22], N-phenylhydroxylamine,  N-(4-chlorophenyl)-
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hydroxylamine,  N-(4-nitrophenyl)-hydroxylamine, 4-chlorobenzohydroxamic acid, 4-
nitrobenzohydroxamic acid, N-phenylbenzohydroxamic acid, N-(4-
methylphenyl)benzohydroxamic acid, N-(4-chlorophenyl)-4-chlorobenzohydroxamic acid) 
[23, 24], N-(2-bromoethyl)phthalimide [25], [Co(tren)(NO2)2]Cl, [Co(tren)Cl2]Cl, 
[Co(tpa)(NO2)2]Cl,  [Co(tpa)Cl2]Cl [26], [Co(tpa)(bhaH–1)](ClO4)2 [11], Na3[Co(CO3)3]·3H2O 
[27] were synthesized and purified according to literature procedures.  
 
2.2 Synthesis of the precursors and complexes 
Compounds 1–3 were prepared by the slight modification of the appropriate literature 
methods. [28-30] 
 
Bis(phtalimidylpropyl)amine (1) 
Phthalic acid anhydride (59.30 g, 0.40 mol) was heated up to 180 oC in a two-neck flask 
equipped with a dropping funnel and condenser. 3,3’-iminobis(propylamine) (28.0 ml, 0.20 
mol) was dropwise added to the melt while vigorous stirring. The reaction mixture was kept at 
180 oC for further 2.5 h and after cooling it was dissolved in hot abs. ethanol (100 ml). On 
cooling at 4 oC overnight and treatment of the bottom phase separated out with a glass rod 
resulted in the formation of a sticky solid. After decantation the solid was homogenized with 
diethylether to obtain a pale brown solid. Recrystallization from hot methanol afforded the 
title compound as a white solid. Yield: 45.72 g (58 %). 1H NMR (360 MHz, DMSO): δ/ppm  
= 8.17–7.50 (m, 8H, Ar-H); 3.62 (t, 4H, -CH2); 2.71 (t, 4H, -CH2); 1.79 (p, 4H, -CH2). 
 
(N-(2-aminoethyl)-N,N-bis(3-aminopropyl)amine, abap (2) 
1 (3.83 g, 9.82 mmol) was melted in a two-neck flask equipped with a condenser and N-(2-
bromoethyl)phthalimide (2.49 g, 9.82 mmol) was added in five portion under vigorous 
stirring. The reaction mixture was strirred in an oil bath at 165 oC for 45 min and let to cool 
down. The resulting glass-like solid was treated with HCl solution (40 ml, 8 M) and refluxed 
overnight. The solution was filtered and the solvent was removed. The resulting sticky solid 
was boiled with ethanol (20 ml) and some drops of water were also added for complete 
dissolution. On cooling overnight at 4 oC the resulting white crystals were filtered, washed 
with a small amount of ethanol and dried in vacuo. Yield: 400 mg (23 %). 1H NMR: (400 
MHz, D2O): δ/ppm = 3.65-3.55 (m, 1H -CH2); 3.55-3.45 (m, 1H -CH2); 3.45-3.35 (m, 2H, -
CH2); 3.25-3.10 (m, 8H, (CH2)4); 2.25-2.05 (m, 4H, -CH2). 
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(2-aminoethyl)bis(2-piridylmethyl)amine, uns-penp (3) 
N-acetylethylenediamine (3.36 g, 30 mmol) was dissolved in dry C2H4Cl2 (150 ml) under 
nitrogen in a two-neck flask. Pyridine-2-carboxaldehyde (5.7 ml, 60 mmol) was dropwise 
added and to the yellow solution NaBH(OAc)3 (18.06 g, 84.9 mmol) was added at positive 
nitrogen pressure. The milky reaction mixture was stirred for 3 h and the reaction was 
quenched by adding NaOH solution (300 ml, 2 M). The organic phase was separated and 
extracted twice with 150 ml of CH2Cl2. The combined organic phase was washed with 150 ml 
of saturated NaCl solution and dried over MgSO4 overnight. After filtering and removing the 
solvent the crude product was recrystallized from acetonitrile. The acetyl protected derivative 
was subjected to hydrolysis in HCl (120 ml, 5 M) via 24 h reflux. The pH of the resulting 
solution was set to 12 with solid KOH and the orange oil separated was extracted with 3x 100 
ml of CH2Cl2. After drying on MgSO4 and filtration the solvent was removed and the 
resulting crude oil was extracted 3 x 50 ml of diethylether. Removal of the solvent afforded 
the title compound as pale yellow oil. Yield: 2.50 g, 34 %. 1H NMR: (360 MHz, D2O): δ/ppm 
= 8.66 (d, 2H, Py-H); 8.47 (t, 2H, Py-H); 8.01 (d, 2H, Py-H); 7.90 (t, 2H, Py-H); 4.22 (s, 4H, -
CH2); 3.22 (t, 2H, -CH2); 3.02 (t, 2H, -CH2). 
 
[Co(uns-penp)(H2O)Cl]Cl2·H2O (4) 
3 (250 mg, 1.03 mmol) was dissolved in water (11 ml), KOH (173 mg, 3.09 mmol), 
CoCl2·6H2O (245 mg, 1.03 mmol) and NaNO2 (142 mg, 2.06 mmol) were added. Via the dark 
solution oxygen was bubbled for 4 h and the solvent was removed. The black purple nitrito 
complex was dissolved in conc. HCl (5 ml) and evaporated to dryness in a steam bath. 
Recrystallization from water afforded the title compound as purple crystalline solid. Slow 
evaporation of the mother liquor resulted in the formation of single crystals directly suitable 
for X-ray analysis. Yield: 127 mg, 32 %. 1H NMR (360 MHz, D2O): δ/ppm = 9.29 (d, 2H, Ar-
H); 8.22 (t, 2H, Ar-H); 7.74 (m, 4H, Ar-H); 5.19 (d, 2H, -CH2); 4.65 (d, 2H, -CH2); 3.25 (t, 
2H, -CH2); 2.06 (t, 2H, -CH2). IR (KBr)/cm–1: 3488, 3423, 3030, 2965, 1613, 1446, 775. MS 
(ESI-TOF): m/z 299.065 [Co(uns-penp)-2H]+ (simulated: 299.070). UV-Vis (λmax(nm)/ε(M-
1cm-1)) : 371(131), 533(127). 
 
[Co(abap)Cl2]ClO4 (5) 
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To Na3[Co(CO3)3]·3H2O (400 mg, 1.11 mmol) suspended in water (4 ml) abap (2) (419 mg,  
1.11 mmol) dissolved in water (2.5 ml) was dropwise added while strirring. The brown 
reaction mixture was heated up to 75 oC within 1 h and kept at 75 oC for further 3 h. The 
resulting dark violet solution was evaporated to ¼ of the volume and treated with HClO4-
soltion (0.13 ml, 60 %) and ethanol (5 ml). Cooling at 4 oC overnight afforded a dark violet 
crystalline solid as title compound. It was filtered washed with ether and dried in vacuo. 
Yield: 220 mg (49 %) 1H NMR: (400 MHz, D2O): δ/ppm = 3.23-1.92 (m, 16H, -CH2). IR 
(KBr)/cm–1: 3199, 3120, 1600, 1543, 1465, 1099, 624. MS (ESI-TOF): m/z 231.102 
[Co(abap)-2H]+ (simulated: 231.101). UV-Vis (λmax(nm)/ε(M-1cm-1)) : 530(69). 
 
 
[Co(tren)(bhaH
–1)]ClO4 (6) 
[Co(tren)Cl2]Cl (1.00 g, 3.00 mmol) (30 ml) and benzohydroxamic acid (520 mg, 3.8 mmol) 
were dissolved in water and KOH (10 ml, 1 M) was added dropwise. The reaction mixture 
was stirred at 70 oC for 6 h. The solvent was almost completely removed and the black solid 
crystallized out was dissolved in ethanol (20 ml). The solution was treated with saturated 
ethanolic NaClO4 solution (8 ml). On cooling overnight at 4 oC the title compound appeared 
as black needles in a 4:3 mixture of the two isomers. The product was filtered off and dried in 
vacuo. Yield: 1.04 g, 79 %. 1H NMR of the major isomer (360 MHz, D2O): δ/ppm = 7.86 (d, 
2H, Ar-H); 7.43 (m, 3H, Ar-H); 3.87 (m, 2H, tren-H); 3.28-2.90 (m, 10H, tren-H). 1H NMR of 
the minor isomer (360 MHz, D2O): δ/ppm = 7.71 (d, 2H, Ar-H); 7.43 (m, 3H, Ar-H); 3.53 (m, 
2H, tren-H); 3.28-2.90 (m, 10H, tren-H). IR (KBr)/cm–1: 3312, 3087, 1464, 1348, 1102, 624. 
MS (ESI-TOF): m/z 340.110 [Co(tren)(bhaH
–1)]+ (simulated: 340.118). UV-Vis 
(λmax(nm)/ε(M-1cm-1)) : 466sh(129), 567(138). 
 
 
[Co(tren)(bha)](ClO4)2 (7) 
6 (200 mg, 0.45 mmol) was suspended in water (4 ml) and HClO4 solution (5 ml, 0.1 M) was 
added. The red solution was stirred for 20 min, evaporated to 2 ml and the crystalline solid 
separated out on standing at 4 oC overnight was filtered off. The purple solid as a 2:1 mixture 
of the two isomers was dried in vacuo. Yield: 140 mg, 57 %. 1H NMR of the major isomer 
(360 MHz, d6-DMSO): δ/ppm = 12.76 (s, 1H, NH); 7.90 (d, 2H, Ar-H); 7.54 (m, 3H, Ar-H); 
5.11 (m, 4H, NH2); 4.56 (s, 2H, NH2); 3.54 (m, 2H, tren-H); 3.34-2.71 (m, 10H, tren-H). 1H 
NMR of the minor isomer (360 MHz, d6-DMSO): δ/ppm = 12.82 (s, 1H, NH); 7.80 (d, 2H, 
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Ar-H); 7.54 (m, 3H, Ar-H); 5.31 (s, 2H, NH2); 5.11 (m, 2H, NH2); 4.76 (s, 2H, NH2); 3.34-
2.71 (m, 12H, tren-H). IR (KBr)/cm–1:3302, 3260, 1611, 1476, 1096, 1046, 925, 697, 623. 
MS (ESI-TOF): m/z 340.111 [Co(tren)(bha-H)]+ (simulated: 340.118). UV-Vis 
(λmax(nm)/ε(M-1cm-1)) : 390sh(167), 526(169). 
 
[Co(tren)(NO2-bha)]Cl2 (8) 
[Co(tren)Cl2]Cl (660 mg, 2.00 mmol) was dissolved in water (20 ml) and 4-
nitrobenzohydroxamic acid (403 mg, 2.2 mmol) and KOH (123 mg, 2.2 mmol) were added. 
The reaction mixture was stirred at 70 oC for 6 h. The brown solid obtained on standing 
overnight at 4 oC was filtered off and recrystallized from hot methanol. Yield: 140 mg, 15 %. 
1H NMR (360 MHz, D2O): δ/ppm = 8.35 (d, 2H, Ar-H); 8.09 (d, 2H, Ar-H); 3.85 (m, 2H, 
tren-H); 3.46-2.89 (m, 10H, tren-H). IR (KBr)/cm–1: 3427, 3187, 3105, 1594, 1523, 1476, 
1349, 852. MS (ESI-TOF): m/z 385.109 [Co(tren)(NO2-bha)-H]+ (simulated: 385.103). UV-
Vis (λmax(nm)/ε(M-1cm-1)) : 548(179). 
 
 
[Co(tren)(NO2-bha)](ClO4)2 (9) 
The mother liquor of the reaction to prepare 8 was evaporated, the solid obtained was 
dissolved in ethanol and treated with saturated ethanolic NaClO4 solution (8 ml). Slow 
evaporation at 4 oC afforded a red microcrystalline solid. Yield: 260 mg, 22 %. 1H NMR (360 
MHz, D2O): δ/ppm = 8.34 (d, 2H, Ar-H); 7.98 (d, 2H, Ar-H); 3.51 (m, 2H, tren-H); 3.44-2.87 
(m, 10H, tren-H). IR (KBr)/cm–1: 3305, 3256, 1590, 1528, 1480, 1351, 1141, 1102, 1034, 
625. MS (ESI-TOF): m/z 385.109 [Co(tren)(NO2-bha)-H]+ (simulated: 385.103). UV-Vis 
(λmax(nm)/ε(M-1cm-1)) : 539(214). 
 
 
[Co(tren)(Cl-bha)](ClO4)2 (10) 
It was synthesized analogously to 9 using [Co(tren)Cl2]Cl (660 mg, 2.01 mmol), 4-
chlorobenzohydroxamic acid (377 mg, 2.21 mmol) and KOH (123 mg, 2.2 mmol). The 
reaction mixture was almost completely evaporated and the resulting crude crystalline solid 
was dissolved in ethanol (10 ml) and treated with saturated ethanolic NaClO4 solution (8 ml). 
On cooling the title compound appeared as claret coloured solid. Recrystallization from 
methanol resulted in the formation of mainly isomer I. Yield: 430 mg, 37 %. Slow 
evaporation of the mother liquor afforded dark purple crystals identified as mainly isomer II. 
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Both products contain a small amount of the other isomer. Yield: 160 mg, 14 %. 1H NMR of 
isomer I (360 MHz, D2O): δ/ppm = 7.85 (d, 2H, Ar-H); 7.55 (m, 2H, Ar-H); 3.83 (m, 2H, 
tren); 3.43-2.88 (m, 10H, tren). 1H NMR of isomer II (360 MHz, D2O): δ/ppm = 7.74 (d, 2H, 
Ar-H); 7.55 (m, 2H, Ar-H); 3.49 (m, 2H, tren-H); 3.43-2.88 (m, 10H, tren-H). IR (KBr)/cm–1: 
3443, 3217, 3114, 1628, 1143, 1113, 1089, 636, 627. MS (ESI-TOF): m/z 374.086 
[Co(tren)(Cl-bha)-H]+ (simulated: 374.079). UV-Vis (λmax(nm)/ε(M-1cm-1)) : 427sh(103), 
524(135). 
 
[Co(tren)(phebha)](ClO4)2 (11) 
[Co(tren)Cl2]Cl (270 mg, 0.835 mmol) was dissolved in water (10 ml) and N-
phenylbenzohydroxamic acid (176 mg, 0.84 mmol) and KOH (50 mg, 0.90 mmol) were 
added. The reaction mixture was stirred at 60 oC for 6 h. Removal of the solvent and treatment 
of the ethanolic solution of the complex with ethanolic NaClO4 solution afforded the title 
compound on cooling as purple crystalline solid. Slow evaporation of the mother liquor gave 
single crystals directly suitable for X-ray diffraction. Yield: 230 mg, 45 %. 1H NMR (360 
MHz, D2O): δ/ppm = 7.93-7.30 (m, 10H, Ar-H); 3.94-3.78 (m, 2H, tren-H); 3.70-2.79 (m, 
10H, tren-H). IR (KBr)/cm–1: 3300, 3260, 1591, 1097, 696, 624. MS (ESI-TOF): m/z 416.141 
[Co(tren)(phebha)-H]+ (simulated: 416.149). UV-Vis (λmax(nm)/ε(M-1cm-1)) : 428sh(152), 
520(168). 
 
[Co(tren)(ClCl-phebha)](ClO4)2  (12) 
This was synthesized as 11 using N-(4-chlorophenyl)-4-chlorobenzohydroxamic acid (233 
mg, 0.83 mmol). Yield: 260 mg, 46 %. 1H NMR (360 MHz, D2O) δ: 7.52-7.30 (m, 8H, Ar-H) 
3.95-3.77 (m, 2H, tren-H) 3.65-2.69 (m, 10H, tren-H). IR (KBr)/cm–1: 3445, 3201, 3109, 
1599, 1142, 1115, 635, 627. MS (ESI-TOF): m/z 484.062 [Co(tren)(ClCl-phebha)-H]+ 
(simulated: 484.071). UV-Vis (λmax(nm)/ε(M-1cm-1)) : 408sh(242), 513(147). 
 
[Co(tren)(Me-phebha)](ClO4)2  (13) 
This was synthesized as 11 using N-(4-methylphenyl)-benzohydroxamic acid (188 mg, 0.83 
mmol). Yield: 210 mg, 40 %. 1H NMR (360 MHz, D2O) δ/ppm = 7.53-7.18 (m, 9H, Ar-H) 
3.97-3.81 (m, 2H, tren-H) 3.70-2.72 (m, 10H, tren-H) 2.39-2.30 (m, 3H, Me). IR (KBr)/cm–1: 
3443, 3306, 3270, 1108, 1092, 626. MS (ESI-TOF): m/z = [Co(tren)(Me-phebha)]2+ 215.6 
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(simulated = 215.6). MS (ESI-TOF): m/z 430.155 [Co(tren)(Me-phebha)-H]+ (simulated: 
430.165). UV-Vis (λmax(nm)/ε(M-1cm-1)) : 431sh(115), 509(113). 
 
[Co(tpa)(bhaH
–1)](ClO4)2 (14) 
It was synthesized as 11 using [Co(tpa)Cl2]Cl (1.00 g, 2.2 mmol), benzohydroxamic acid (310 
mg, 2.2 mmol) and KOH (5.5 mmol). Yield: 900 mg, 70 %. 1H NMR (400 MHz, d6-DMSO): 
δ/ppm = 9.58 (d, 1H Ar-H); 9.22 (d, 1H, Ar-H); 8.55 (d, 1H, Ar-H); 8.18 (t, 1H, Ar-H); 8.00-
7.86 (m, 3H, Ar-H); 7.75-7.60 (m, 3H, Ar-H); 7.52-7.43 (d, 3H, Ar-H); 7.41-7.30 (m, 3H, Ar-
H); 7.13 (d, 1H, Ar-H); 5.62 (d, 1H, -CH2); 5.32 (t, 2H, -CH2); 5.15 (m, 2H, -CH2); 5.06-5.00 
(m, 1H, CH2). IR (KBr)/cm–1: 3545, 3420, 3055, 2970, 2016, 1610, 1445, 1341, 773, 624. MS 
(ESI-TOF): m/z 484.107 [Co(tpa)(bhaH
–1)]+ (simulated: 484.118). UV-Vis (λmax(nm)/ε(M-
1cm-1)) : 450sh(136), 595(151). 
 
[Co(tpa)(bha)](ClO4)2·C2H5OH·H2O (15) 
14 (263 mg, 0.45 mmol) was suspended in water (10 ml), HClO4 solution (5 ml, 0.1 M) was 
added and stirred for 3 h. The color of the reaction mixture turned to pink. The crystalline 
solid was filtered off, washed with water and dried in vacuo. Slow evaporation of the solution 
gave single crystals. Yield: 200 mg, 64 %. 1H-NMR (400 MHz, d6-DMSO): δ/ppm = 8.81 (d, 
1H, Ar-H); 8.59 (d, 2H, Ar-H); 8.37-8.24  (dd, 1H, Ar-H); 8.20-8.10 (m, 2H, Ar-H); 7.87-7.57 
(m, 8H, Ar-H); 7.57-7.49 (m, 1H, Ar-H); 7.46-7.37 (m, 3H, Ar-H); 5.74 (d, 2H, -CH2); 5.42-
5.12 (m, 4H, -CH2). IR (KBr)/cm–1: 3525, 3113, 3083, 2017, 1475, 1441, 924, 776, 624. MS 
(ESI-TOF): m/z 484.107 [Co(tpa)(bha)-H]+ (simulated: 484.107). UV-Vis (λmax(nm)/ε(M-1cm-
1)) : 443sh(167), 544(246). 
 
[Co(tpa)(phebha)](ClO4)2 (16) 
It was synthesized as 11 using [Co(tpa)Cl2]Cl (0.50 g, 1.1 mmol) and N-
phenylbenzohydroxamic acid (235 mg, 1.1 mmol). Yield: 580 mg, 63%. 1H NMR (400 MHz, 
DMSO): δ/ppm = 9.37 (d, 1H, Ar-H); 8.77 (d, 2H, Ar-H); 8.54 (d, 1H, Ar-H); 8.21 (t, 2H, Ar-
H); 8.08-7.93 (m, 1H, Ar-H); 7.89-7.56 (m, 8H, Ar-H); 7.53-7.12 (m, 6H, Ar-H); 6.92 (d, 1H, 
Ar-H); 5.74 (d, 2H, -CH2); 5.30 (m, 4H, -CH2). IR (KBr)/cm–1: 3566, 3420, 3059, 2981, 2007, 
1747, 1611, 1549, 1492, 1421, 770, 624. MS (ESI-TOF): m/z 560.136 [Co(tpa)(phebha)-H]+ 
(simulated: 560.149). UV-Vis (λmax(nm)/ε(M-1cm-1)) : 428sh(146), 536(136). 
 
2.3 NMR, IR and ESI-MS measurements 
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NMR measurements were carried out using Bruker Avance 360 or 400 NMR spectrometers at 
room temperature on samples prepared in D2O or d6-DMSO. Calibration was performed using 
the isotopic impurities of the solvents. IR spectra as KBr pellets were recorded on a Perkin 
Elmer FTIR Paragon 1000 PC instrument at the Department of Organic Chemistry, University 
of Debrecen. ESI-TOF MS measurements in the positive mode were carried out on a Bruker 
micrOTOF-Q instrument at the Department of Applied Chemistry, University of Debrecen. 
  
2.4 Cyclic voltammetric studies 
Cyclic voltammetric experiments were performed at room temperature in aqueous solution 
using a Metrohm 746-747 VA Trace Analyser equipped with a three-electrode system, which 
consists of a Ag/AgCl/3M KNO3 reference electrode (E1/2 = 209 mV vs. NHE), a platinum 
wire auxiliary electrode (ALS Co. Japan), and a glassy carbon (CHI104) working electrode. 
Aqueous solution of K3[Fe(CN)6] was used to calibrate the system (E1/2 = 0.458 V versus 
NHE in 5 × 10-1 mol dm-3 KCl) [31]. The samples were degassed before the measurements 
using argon gas. The concentration of the complexes was 5 or 10 mM, the potential sweep 
rates were varied within the range 200-500 mV s− 1 during the determination of the redox 
potentials. In all cases, KNO3 (0.20 M) was used as supporting electrolyte. 
 
2.5 Crystal structure analysis 
Diffraction intensity data collection was carried out at 293(2) K on a Bruker-Nonius MACH3 
diffractometer equipped with an area detector using graphite-monochromated Mo-Kα 
radiation (λ = 0.71073 Å) or on a SuperNova diffractometer equipped with an Atlas detector 
using Cu-Kα radiation (λ = 1.5418 Å) at 293(2) K. The structures were solved by SIR-92 
program [32] and refined by full-matrix least-squares method on F2. Non-hydrogen atoms 
were refined anisotropically using the SHELX package [33]. Publication material was 
prepared with the WINGX- suite [34] and publCIF [35]. Hydrogen atoms were placed into 
calculated positions and refined in the rigid mode except the O-H and N-H protons which 
could be found at the difference electron density map and the respective O-H and N-H 
distances were constrained. Complex 11 crystallized in chiral space group of C2 with one 
molecule in the asymmetric unit. Structure 11 overlayed with its inverted pair is shown in 
Figure S1. The synthesis route was achiral and no further research was performed to detect 
the possibility of chiral induction. In structure 15 the solvent ethanol shows slight disorder. 
Crystallographic and experimental details are summarized in Table 1. Crystallographic data 
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and refinement details for 4, 11, 15 and 16 are deposited in the Cambridge Crystallographic 
Data Centre under CCDC 1546197-1546200. 
 
Figure S1. 
Table 1. 
 
3. Results and discussion 
 
3.1 Characterization of the precursors and complexes 
Some of the already published amine ligands or complexes were synthesized by the slight 
modification of published methods while for the preparation of most of the novel Co(III) 
ternary complexes one of the literature methods were used. All the compounds were 
characterized with NMR and IR methods. For some of the new Co(III) complexes the 
molecular structure was identified using single crystal X-ray diffraction method. 
1H-NMR spectra of the ternary Co(III) complexes showed the expected resonances, although, 
in agreement with previous findings [12], non-equivalence of the aliphatic protons of tren as 
well as those in tpa resulted in the appearance of signals with high multiplicity. Although it 
was beyond the scope of our work, in some cases the isomers of the 
[Co(tren/tpa)hydroxamate] complexes, being present due to the non-symmetrical structure of 
the coordinating (O,O) donor hydroxamates, were also identified and quantified. As an 
example, COSY spectrum of the aromatic region of [Co(tpa)(bha)]2+ is shown in Figure 1. 
 
Figure 1. 
 
As it is seen in Fig. 1 two sets of cross peaks belonging to the major and minor isomers 
(identified by the ratios of the corresponding signal areas) can be detected. For both isomers 
the presence of two set of signals is the consequence of the presence of a mirror plane within 
the complex cation making non-equivalent of the pyridyl ring being in this place with the two 
other symmetry-equivalent pyridyl units out of the plane.     
For [Co(uns-penp)(H2O)Cl]Cl2·H2O (4), containing the tripodal ligand with an aliphatic and 
two pypidyl arms, and in the case of some new tren or tpa ternary hydroxamate complexes, 
11, 15 and 16, the molecular structures were also proven by X-ray diffraction. In every cases, 
in accordance with previous results on similar Co(III) complexes [12], the expected 
octahedral geometry around the central metal ion was found with the N-Co-N or N-Co-O 
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bond angles being around 180o. For the Co-N or Co-O distances (Table 2) the measured 
values are in the range of the typical values for [Co(tren/tpa)(hydroxamate)] type complexes 
[12]. 
 
Table 2 
 
Although high chloride concentration was used to convert the nitrito precursor to the mixed 
ligand chlorido complex for 4, the structure (Fig. 2) indicated the presence of one water and 
one chloride ligand beside the tripodal amine in the coordination sphere of the metal ion.  
 
Figure 2 
 
As far as the benzohydroxamato (protonated hydroxamate-NH) ternary complex, 
[Co(tpa)(bha)](ClO4)2·C2H5OH·H2O (15), is concerned, due to rigid structures no significant 
differences in the appropriate bond distances compared to the benzohydroximato 
(deprotonated hydroxamate-N) species, [Co(tpa)(bhaH
-1)]+ [11], were found with the 
exception that in 15 (Fig. 3) H-bonding is detected between the hydroxamate NH as donor 
and the water molecule as acceptor. Interestingly, the orientation of the benzohydroxamate 
and benzohydroximate ligands are opposite in the two structures, i.e. the carbonyl O is trans 
or cis to the aliphatic N of tpa, respectively. Comparison of the two new, phebha-containing 
stuctures with tren (11) (Fig. S2) and tpa (16) (Fig. 4) reveals higher steric hindrance of the 
pyridyl arms of tpa than those of the alphatic ones of tren resulting in significantly different 
Co-O(N) and Co-O(C) distances in 16 while these values are practically identical for 11 
(Table 2). Overlay of the two structures indicates the very similar orientation of the phenyl 
substituents of the hydroxamic acids in the two complexes (Fig. S3).  
 
Figure 3 
Figure S2 
Figure 4 
Figure S3 
 
3.2 Electrochemical results on some precursor complexes  
The electrochemical properties of some precursor Co(III) complexes, as well as those of all 
the investigated ternary complexes have been analysed under the conditions given in Section 
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2.4. Catodic peaks (Epc) in all cyclic voltammograms (CVs) were observable indicating 
clearly the reduction of the complexes, while lack of anodic peaks (Epa) provided evidence 
about default of anodic, reoxidation upon scan reversal. Namely, irreversible reduction of the 
complexes occured in all of the investigated systems under the conditions used.   
Out of the precursor complexes, the tpa- and tren-containing ones (especially with chloride 
ancillary ligand(s)) have been previously investigated in some laboratories [11, 12, 21], but, to 
the best of our knowledge, this is the first time, when some electrochemical results are 
provided on the complexes [Co(abap)Cl2]ClO4 and [Co(uns-penp)(H2O)Cl]Cl2. With tpa and 
tren, in addition to their chlorido complexes, also the nitrito ones have been electrochemically 
studied in the present work. For illustration, CVs registered for [Co(tren)Cl2]Cl, 
[Co(tpa)Cl2]Cl, [Co(abap)Cl2]ClO4 and [Co(uns-penp)(H2O)Cl]Cl2 are presented in Figure 5. 
The calculated cathodic peak potentials compared both to Ag/AgCl and NHE reference 
electrodes are collected in Table 3. 
 
Figure 5 
Table 3 
As Table 3 and Figure 5 show, the Co(III)/(II) reduction potentials of the complexes with tren 
are significantly more negative than those of the corresponding tpa complexes. This is in 
complete agreement with previous literature results [12, 17] and explained by the capability of 
the three pyridyl rings of tpa for pi-back-bonding interaction with the metal centre resulting in 
lowering of its electron density and positive shift of Co(III)/Co(II) redox potential. This 
assumption is also supported by the reduction potential of the complex of uns-penp. In this 
latter ligand only two of the three arms contain pyridyl rings, the third involves amine 
nitrogen, and, in fact, the Epc value lies between those for the complexes of tpa and tren (see 
Table 3). Surprising result was obtained, however, with abap. As it is clearly seen in Figure 5, 
the reduction potential of [Co(abap)Cl2]ClO4 is far the most negative of the investigated 
precursors and is significantly more negative even compared to that of the tren-containing 
complex. If we try to understand the background of this significant decreasing of the redox 
potential, we can take into account that two arms of abap are longer with one CH2 moiety 
compared to tren, what, according to the literature, results in somewhat higher overall basicity 
[20] and, as a consequence, possibility of a slightly higher σ-donation ability of the amine 
nitrogens of abap might be reasonable. However, for the more adequate explanation of this, 
somehow unexpected result needs additional investigation. Anyway, it seems that the redox 
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potential of the abap-containing complex is far below the region, where reduction of the 
central Co(III) by biological redox systems would be realistic.   
As it can be expected, electron donating capability of the nitrite moiety results in measurably 
negative shift of the reduction potentials of its complexes (see Table 3) compared to the 
corresponding choride-containing ones. 
 
3.3 Electrochemical results on the ternary complexes incorporating hydroxamates  
All the previous results on Co(III) ternary complexes formed with the involvement of a 
tripodal tetraamine (tren or tpa) and a mono- or doubly-deprotonated form of benzo- [11,12],  
aceto- [11, 21], propiono- [11] or 1-napthylacetohydroxamic acid [12] and also our 
corresponding values (see Table 3) demonstrate that the 3+ oxidation state of the central metal 
ion is very much stabilized in the complexes containing doubly deprotonated hydroxymato 
ligands and it can be reduced at far more negative potential than the region of the biological 
reductants.  As Table 3 also shows, with the monoanionic hydroxamate, bha–, if the ancillary 
ligand is tpa, the reduction potential is adequate to the region, where biological reductants 
might be able to reduce the Co(III) ion. This is not the case with tren, however, the complexes 
of which are far less reducable. It is an interesting question, whether there is some possibility 
to tune the Co(III)/(II) reduction potential into the above-mentioned region via modification 
of the hydroxamate ligand. Relevant information to this question was aimed to find, when a 
series of bhaH derivatives have been synthesized (see Scheme 1 for their formulae) and, first 
of all, their ternary complexes with tren ancillary ligand have been investigated in 
electrochemical studies in the present work.  
The following conclusion can be drawn by analysing the corresponding redox potential values 
in Table 3: (i) Only a small, if any effect was found on the redox potential via introduction of 
chloro or nitrito substituent in para position into the phenyl moiety of bha– (Cl-bha– and NO2-
bha–). To illustrate this conclusion, CV curves recorded for the [Co(tren)bha](ClO4)2 and 
[Co(tren)4-Cl-bha](ClO4)2 complexes are shown on the same figure in the Supplementary part 
(Fig. S4) (This result is in agreement with those obtained for Co(III)-acetohydroxamate-tpa 
derivative ternary complexes. No effect was found on the redox potential, when introduction 
of chloro substituents on tpa was made [21]).  (ii) Significant positive shift (ca. 200 mV) was 
obtained, however, when RN = H was substituted by a phenyl ring in phebha– and the 
reduction of this complex may become imaginable by bio-reductants. For comparison, with 
this ligand, not only the tren-containing ternary complex was investigated, but also the tpa-
containing one and exactly the same positive shifts of the values (see Table 3) were identified 
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for both complexes. (iii) Introduction of chloro or methyl substituent in one or both of the two 
phenyl moieties of phebha– did not cause any significant further change in the reducibility of 
the complexes.     
Figure S4 
 
Conclusions 
 
As potential carriers and deactivators of benzohydroxamate-based bioactive molecules, 
Co(III) complexes of four tripodal tetramines, tris(2-aminoethyl)amine (tren), tris(2-
pyridylmethyl)amine (tpa), N-(2-aminoethyl)-N,N-bis(3-aminopropyl)amine (abap) and 2-
aminoethyl)bis(2-piridylmethyl)amine (uns-penp), being the ancillary ligands either chloride 
or nitrite ions, have been prepared and characterized by NMR, IR, ESI-TOF-MS, UV-Vis, 
cyclic voltammetry, and by X-ray in the case of the complex [Co(uns-penp)(H2O)Cl]Cl2, as 
well as the influence of the structural differences of the amines on the redox activity of the 
central Co(III/II) couple was also studied. The first two amines have been already used in 
numerous previous studies to develop hypoxia-selective cobalt complexes, but, to the best of 
our knowledge, this is the first case, when the latter two are investigated with this goal. 
Irreversible reduction of Co(III) was observed in all the investigated complexes and the 
highest reduction potential was identified for the tpa-containing complex (+281 mV vs. 
NHE), where the three pi-back-bonding pyridyl rings produce the highest decrease of the 
electron density on the metal centre. Compared to this, ca. 250 mV negative shift was 
detected for the complex of uns-penp containing two pyridyl rings and one amine moiety in 
the chains. Additional ca. 250 mV negative shift is observed with tren, containing three 
aliphatic amines. Surprisingly, an increase of two chains by one CH2 group each in abap 
compared to tren, results in sharp decrease of the redox potential (-564 mV vs. NHE) making 
the bioreduction of this complex highly unlikely.  
The tren-containing precursor complex was used to prepare and characterize seven ternary 
complexes with various derivatives of bhaH, while three complexes were prepared and 
characterized with tpa. For three complexes, [Co(tren)(phebha)](ClO4)2, 
[Co(tpa)(bha)](ClO4)2·C2H5OH·H2O and [Co(tpa)(phebha)](ClO4)2, the molecular structures 
were also proven by X-ray diffraction. In agreement with the literature results it was found 
that the +3 oxidation state of the central cobalt-ion is extremely stabilized in the ternary 
complexes containing the doubly deprotonated benzohydroximate, but the metal ion is 
significantly more reducible in the ternary complexes with mono-deprotonated 
  
17 
 
benzohydroxamate/derivative ligands. Measurable effect was not observed on the redox 
potential via introduction of chloro or nitro substituent in para position into the phenyl moiety 
of bha– (Cl-bha– and NO2-bha–). Significant positive shift (ca. 200 mV) was obtained, 
however, when RN = H was substituted by a phenyl ring in phebha– therefore complexes with 
this latter ligand can be likely candidates for the in vitro releasing of hydroxamates with 
proven biological activity. 
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Figure 1. Aromatic region of the COSY spectrum of [Co(tpa)(bha)](ClO4)2 in d6-DMSO.  
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Figure 2. ORTEP view of the [Co(uns-penp)(H2O)Cl]2+ cation of (4) at 50 % probability level. 
The chloride counter ions and the solvent water molecule are not shown for clarity. 
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Figure 3. ORTEP view of the [Co(tpa)(bha)]2+ cation of 15 at 50% probability level. The 
perchlorate counter ions, the solvent C2H5OH and the water molecule are not shown for 
clarity. 
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Figure 4. ORTEP view of the [Co(tpa)(phebha)]2+ cation of 16 at 50 % probability level. The 
perchlorate counter ions are not shown for clarity. 
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Figure 5. CV curves registered for [Co(tpa)Cl2]Cl (a), [Co(uns-penp)(H2O)Cl]Cl2 (b), [Co(tren)Cl2]Cl (c) 
and Co(abap)Cl2]ClO4 (d) in water, referenced to Ag/AgCl electrode at a potential sweep rate of 200 
mV/s and cM = 1.0 mM. 
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Scheme 1 
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  Table 1. Crystallographic parameters and refinement details for the Co(III) complexes  
 
 
 
 
 
 
 
 
  
Chemical formula 2(C14H20ClCoN4O)·Cl4·H2O (4) C19H28CoN5O2·2(ClO4) (11) C25H24N5O2Co· 2(ClO4)·C2H6O· H2O 
(15) 
C31H28CoN5O2· 2(ClO4) (16) 
Mr 869.25 616.29 748.4 760.41 
Crystal system, space group Monoclinic, Cc Monoclinic, C2 Monoclinic, P21/n Monoclinic, Cc 
Temperature (K) 293 293 298 298 
a, b, c (Å) 12.8726 (2), 7.7648 (1), 18.7982 (3) 16.4658 (3), 7.7014 (1), 21.5468 (4) 12.712 (1), 12.862 (2), 20.234 (3) 9.122 (3), 18.174 (4), 19.752 (5) 
β (°) 97.532 (1) 111.214 (2) 98.92 (1) 100.04 (2) 
V (Å3) 1862.73 (5) 2547.19 (8) 3268.3 (7) 3224.5 (15) 
Z 2 4 4 4 
Radiation type Cu Kα Cu Kα Mo Kα Mo Kα 
µ (mm-1) 11.28 7.78 0.76 0.77 
Crystal size (mm) 0.30 × 0.30 × 0.10 0.04 × 0.05 × 0.3 0.4 × 0.3 × 0.25 0.35 × 0.1 × 0.07 
Diffractometer SuperNova, Dual, Cu at zero, Atlas  
diffractometer 
SuperNova, Dual, Cu at zero, Atlas  
diffractometer 
Enraf Nonius MACH3  
diffractometer 
Enraf Nonius MACH3  
diffractometer 
Absorption correction Multi-scan  
CrysAlis PRO 1.171.38.41 (Rigaku 
Oxford Diffraction, 2015) Empirical 
absorption correction using spherical 
harmonics, implemented in SCALE3 
ABSPACK scaling algorithm. 
Multi-scan  
CrysAlis PRO 1.171.38.41 (Rigaku 
Oxford Diffraction, 2015) Empirical 
absorption correction using spherical 
harmonics, implemented in SCALE3 
ABSPACK scaling algorithm. 
ψ scan  
North A.C.T., Phillips D.C. & Mathews 
F.S. (1968) Acta. Cryst. A24, 351  
Number of ψ  scan sets used was 4  
Theta correction was applied.  Averaged 
transmission function was used.  Fourier 
smoothing - Window value 5 
Part of the refinement model (∆F)  
Walker, N. & Stuart, D (1983) Acta. 
Cryst. A39, 158-166 
 Tmin, Tmax 0.148, 1.000 0.322, 1.000 0.647, 0.986 0.295, 0.863 
No. of measured, independent and 
 observed [I > 2σ(I)] reflections 
6733, 3126, 3077   14501, 4854, 4607   6702, 6083, 2470   4607, 4607, 3135   
Rint 0.029 0.027 0.052 0.157 
(sin θ/λ)max (Å-1) 0.621 0.622 0.607 0.603 
R[F2 > 2σ(F2)], wR(F2), S 0.038,  0.103,  1.10 0.071,  0.187,  1.06 0.092,  0.221,  0.93 0.097,  0.220,  1.36 
No. of reflections 3126 4854 6083 4607 
No. of parameters 230 334 432 443 
No. of restraints 8 1 5 2 
H-atom treatment H atoms treated by a mixture of 
independent and constrained 
refinement 
H-atom parameters constrained H atoms treated by a mixture of 
independent and constrained refinement 
H-atom  parameters not refined 
∆〉max, ∆〉min (e Å-3) 0.80, -0.28 2.58, -0.36 0.64, -0.37 0.48, -0.69 
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Table 2. Key bond length values (Å) of the complexes. 
  
Complex C=O N-O Co-O(N) Co-O(C) 
[Co(tren)(phebha)](ClO4)2 (11) 1.331(7) 1.348(7) 1.891(4) 1.892(5) 
[Co(tpa)(bha)](ClO4)2·C2H5OH·H2O (15) 1.291(8) 1.375(7) 1.864(4) 1.885(5) 
[Co(tpa)(phebha)](ClO4)2 (16) 1.308(18) 1.406(16) 1.864(11) 1.901(11) 
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Table 3. Measured cathodic peak potential (Epc) values of the Co(III) complexes referenced to 
Ag/AgCl and the calculated values against NHE.  
 
  
Complex 
Epc (mV) 
Ag/AgCl 
Epc (mV)  
H2/H
+ 
[Co(tren)Cl2]Cl -439 -230 
[Co(tpa)Cl2]Cl 72 281 
[Co(uns-penp)(H2O)Cl]Cl2 -182 27 
[Co(abap)Cl2]ClO4 -773 -564 
[Co(tren)(NO2)2]Cl -568 -359 
[Co(tpa)(NO2)2]Cl  -175  34 
   
[Co(tren)(bha)](ClO4)2 -780 -571 
[Co(tren)(bhaH-1)]ClO4 -999 -790 
[Co(tren)(Cl-bha)](ClO4)2 -782 -573 
[Co(tren)(NO2-bha)](ClO4)2 -726 -517 
[Co(tren)(phebha)](ClO4)2 -572 -363 
[Co(tren)(ClCl-phebha)](ClO4)2 -570 -361 
[Co(tren)(Me-phebha)](ClO4)2 -550 -341 
[Co(tpa)(bha)](ClO4)2 -427 -218 
[Co(tpa)(bhaH-1)](ClO4) -687 -478 
[Co(tpa)(phebha)](ClO4)2 -224 -15 
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Highlights 
• synthesis of Co(III) complexes incorporating hydroxamates  as potential hypoxia-activated 
prodrugs 
• CV study of the complexes to explore the structural and electronic effects of the ligands on 
their redox properties 
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Synopsis for the graphical abstract 
 
Ternary [Co
III
(4N)(hydroxamate] complexes as potential hypoxia-activated chaperons were 
synthesized and the effect of the structural and electronic effects of the ligands on the redox 
behaviour of the complexes was studied using cyclic voltammetry. 
 
 
 
 
